Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Y Liu, SK Barta - American journal of hematology, 2019 - Wiley Online Library
Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
Diffuse large B-cell lymphoma
S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase …
A Davies, TE Cummin, S Barrans, T Maishman… - The Lancet …, 2019 - thelancet.com
Background Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified
using gene-expression analysis to determine their cell of origin, corresponding to germinal …
using gene-expression analysis to determine their cell of origin, corresponding to germinal …
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker …
A Rosenwald, S Bens, R Advani, S Barrans… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma …
K Dunleavy, MA Fanale, JS Abramson, A Noy… - The Lancet …, 2018 - thelancet.com
Background MYC gene rearrangement is present in approximately 10% of aggressive B-cell
lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective …
lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective …
Double hit and double expressors in lymphoma: definition and treatment
PA Riedell, SM Smith - Cancer, 2018 - Wiley Online Library
Emerging biologic subsets and new prognostic markers are significantly and adversely
affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas …
affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas …
KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo–YAP pathway
X Chen, T Lu, Y Cai, Y Han, M Ding, Y Chu… - Cellular & Molecular …, 2023 - Springer
Abstract Background N 6-methyladenosine (m6A) has been shown to participate in various
essential biological processes by regulating the level of target genes. However, the function …
essential biological processes by regulating the level of target genes. However, the function …
Defining and treating high-grade B-cell lymphoma, NOS
High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …
Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas
Purpose: Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and
inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been …
inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been …
First‐line treatment of double‐hit and triple‐hit lymphomas: survival and tolerance data from a retrospective multicenter French study
M Laude, L Lebras, P Sesques… - American journal of …, 2021 - Wiley Online Library
Historically, double or triple hit lymphoma (DHL and THL) have poor outcomes with
conventional chemotherapy, but there is currently no guideline. We report the French …
conventional chemotherapy, but there is currently no guideline. We report the French …